It is amazing chart with invesetor or speculator
5.00$ it is good point to build Buying centers with stop loss under 3.50 $ for short term
First target for speculator 8.00 to8.70$
First Target for invesetor 21$ then 49$
ABEO has a nice Long setup .
Ma cross 32/72 strategy on weekly timeframe
with 1.5 reward to risk ratio .
Entry around 4.78 cents
Stop is at 3.63 cents , which is the low of the bottom of the candle of the MA cross
target is 6.50 cents
, indicators on chart is insane oscillator from Trade oracle all Green ready to roll upside
, Ma cross, 32/72
Abeona Therapeutics Inc is a leading clinical-stage biopharmaceutical company. The Company develops novel gene therapies for life-threatening rare diseases. I guess the stock can surge at least to $4.94.
My trade levels:
Entry: $3.92
Take profit: $4.94
Stop loss: $3.59
Risk/reward: 3.09
** risky investment opportunity, $200m market capital **
Happy with the risk?
On the above 10-day chart price action has corrected a massive 95% from a high of $20 in early 2018. A number of reasons now exist to be bullish. Why?
1) Bullish divergences. Since the ‘great buy’ signal price action has continued to print lower lows while higher lows are printing...
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus...
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus...
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and...
